Inherited skin disorders have been reported recently to have sporadic normal-looking areas, where a portion of the keratinocytes have recovered from causative gene mutations (revertant mosaicism). We observed a case of recessive dystrophic epidermolysis bullosa treated with cultured epidermal autografts (CEAs), whose CEAgrafted site remained epithelized for 16 years. We proved that the CEA product and the grafted area included cells with revertant mosaicism. Based on these findings, we conducted an investigator-initiated clinical trial of CEAs from clinically revertant skin for recessive dystrophic epidermolysis bullosa. The donor sites were analyzed by genetic analysis, immunofluorescence, electron microscopy, and quantification of the reverted mRNA with deep sequencing. The primary endpoint was the ulcer epithelization rate per patient at 4 weeks after the last CEA application. Three patients with recessive dystrophic epidermolysis bullosa with 8 ulcers were enrolled, and the epithelization rate for each patient at the primary endpoint was 87.7%, 100%, and 57.0%, respectively. The clinical effects were found to persist for at least 76 weeks after CEA transplantation. One of the three patients had apparent revertant mosaicism in the donor skin and in the post-transplanted area. CEAs from clinically normal skin are a potentially well-tolerated treatment for recessive dystrophic epidermolysis bullosa.

2020). ACE2 expression is more widely distributed than that of B 0 AT1 (Yan et al., 2020), which may explain why some of the ACE2 expressing organs, such as lung and heart, are attacked by SARS-CoV-2, whereas others are not.Apart from ACE2, there may be another way for SARS-CoV-2 to infect host cells. ACE2 is scarcely present in immune cells. However, most patients with severe acute respiratory syndrome and patients with COVID-19 have lymphopenia; some patients may even have spleen and lymph nodes necrosis (Hamming et al., 2004). Similarly, ACE2 was absent in platelets, but SARS-CoV-2 was detected in platelets from patients with COVID-19 (Manne et al., 2020). These studies suggest that platelets and immune cells may take up SARS-CoV-2 mRNA independent of ACE2.In summary, the work of Xue et al. ( 2020) provides a new perspective on the potential percutaneous transmission of COVID-19, but so far, from the clinical data we summarized, no definitive evidence had shown that there is a transmission of COVID-19 through the skin, especially owing to the difference of ACE2 expression. Anyhow, we should still attach importance to this potential transmission route owing to the fact that human coronavirus is an RNA virus with high mutation potential.

We successfully established iPSC-derived MSCs from keratinocytes (KC-iPSC-MSCs) of a normal human and an RDEB patient. KC-iPSC-MSCs may have potential in therapies for RDEB.

These results suggest that fluctuations in chemokine levels may contribute in a coordinated way to the wound-healing process and lend clues toward efficient cell therapies for EB.

Sci, Vol. 10, No. 2, pp. 129-132, 2011 We report magnetic resonance (MR) imagingˆndings of ductal carcinoma in situ (DCIS) within aˆbroadenoma in a 42-year-old woman. Dynamic MR imaging revealed the mass to have 2 components with diŠerent kinetics. A nodular area within the mass showed faster initial enhancement followed by earlier washout and was histologically proven to be DCIS. Dynamic MR imaging re‰ected diŠerences in vascularity between theˆbroadenoma and DCIS, and parameter color maps generated from the dynamic data clearly demonstrated the extent of the DCIS.